Particle and Heavy Ion Transport Code System-Based Microdosimetry for the Development of Boron Agents for Boron Neutron Capture Therapy,Advanced Theory and Simulations

当前位置： X-MOL 学术 › Adv. Theory Simul. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Particle and Heavy Ion Transport Code System-Based Microdosimetry for the Development of Boron Agents for Boron Neutron Capture Therapy
Advanced Theory and Simulations ( IF 2.9 ) Pub Date : 2023-04-28 , DOI: 10.1002/adts.202300163
Takafumi Shigehira ₁ , Tadashi Hanafusa ₂ , Kazuyo Igawa ₂ , Tomonari Kasai ₂ , Shuichi Furuya ₃ , Hisakazu Nishimori ₄ , Yoshinobu Maeda ₄ , Hiroyuki Michiue ₂ , Atsushi Fujimura _{1,

2}

Affiliation

Boron neutron capture therapy (BNCT) is a radiation therapy that selectively kills cancer cells at the cellular level using the boron neutron capture reaction (BNCR) (10B(n.α)7Li). The amount of boron ¹⁰B delivers in boronophenylalanine (BPA)-BNCT to achieve anti-tumor effects is ≈15–40 ppm. The same is true for all boron drugs; however, whether the same amount of ¹⁰B is required for other boron drugs with different accumulation characteristics has not been intensively investigated. Therefore, herein, a virtual cell model with intracellular organelles is prepared, and the BPA equivalent dose concentration to the cell nucleus is analyzed using particle and heavy ion transport code system-based microdosimetry. Additionally, the intranuclear minimal region (IMR) is set as a reference for the concept of the intranuclear domain in the microdosimetric kinetic model, and the BPA equivalent dose concentration to the IMR is estimated. The required boron delivery dose greatly varies depending on the dose assessment based on the accumulation characteristics of boron agents in intracellular organelles. Evaluation of the BNCR effect according to the accumulation characteristics without being influenced by the specified value of 15–40 ppm is recommended.

中文翻译：

基于粒子和重离子传输代码系统的微剂量测定，用于开发用于硼中子捕获治疗的硼剂

硼中子捕获疗法 (BNCT) 是一种利用硼中子捕获反应 (BNCR) (10B(n.α)7Li) 在细胞水平选择性杀死癌细胞的放射疗法。^{苯丙氨酸硼 (BPA)-BNCT 中硼10} B的含量约为 15–40 ppm，可实现抗肿瘤效果。所有硼药物也是如此；然而，是否同样数量的¹⁰对于具有不同积累特性的其他硼药物所需的B尚未得到深入研究。因此，本文制备了具有细胞内细胞器的虚拟细胞模型，并使用基于粒子和重离子传输代码系统的微剂量测定法分析了细胞核的BPA等效剂量浓度。此外，在微剂量动力学模型中，设定核内最小区域（IMR）作为核内域概念的参考，并估计IMR的BPA等效剂量浓度。所需的硼输送剂量根据基于硼剂在细胞内细胞器中的积累特性的剂量评估而有很大差异。

更新日期：2023-04-28

点击分享查看原文

点击收藏

阅读更多本刊最新论文